Search Results

You are looking at 1 - 6 of 6 items for :

  • "acne-like rash" x
Clear All
Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz and Sharon Spencer

and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [Abstract] . Proc Am Soc Clin Oncol 2003 ; 22 : Abstract 817 . 23 Wacker B Nagrani T Weinberg J . Correlation

Full access

Diane Reidy and Leonard Saltz

. Available at http://www.nccn.org/professionals/physician_gls/default.asp . Accessed August 28, 2007 . 24. Saltz LB . The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple

Full access

Mario E. Lacouture

survival times among patients with grade 3 rash. 1 Acne-like rash emerges first, followed by postinflammatory effects such as dry skin, fissures in palms and soles, and paronychia (nail changes). Unfortunately, surveys have shown a high rate of

Full access

Charu Aggarwal, Neeta Somaiah and George R. Simon

were seen in overall or progression-free survival in patients with (n = 38) or without (n = 161) KRAS mutations who received cetuximab. Patients treated with cetuximab who developed early acne-like rash of any grade had a longer median overall

Full access

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes and Kristina M. Gregory

patients receiving cetuximab (11.3 vs. 10.1 months; P = .04). However, patients receiving cetuximab experienced increased grade 3 or 4 febrile neutropenia (22% vs. 15%; P < .05) and grade 2 acne-like rash. Treatment-related deaths were similar in both

Full access

David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, Mohammad Jahanzeb, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, George R. Simon, Scott J. Swanson, Douglas E. Wood and Stephen C. Yang

patients receiving cetuximab (11.3 vs. 10.1 months, P = .04). However, patients receiving cetuximab experienced increased grade 3 or 4 febrile neutropenia (22% vs. 15%; P < .05), and also experienced grade 2 acne-like rash. Treatment-related deaths were